logo inner

Sr. Scientist I/II or Principal Scientist I - CRISPR Gene Off-Targeting Specificity

Mammoth BiosciencesMammoth Brisbane, California, United StatesOnsite
This job is no longer open
OPPORTUNITY
Mammoth Biosciences is currently seeking a highly skilled and motivated scientist to join our expanding off-target team. You will be at the forefront of advancing our understanding and optimizing Mammoth’s proprietary gene-editing technology, with a particular focus on measuring and minimizing off-target effects. Your expertise and leadership will be pivotal in developing innovative solutions to enhance the precision and safety of gene editing, revolutionizing the field of genome engineering.

KEY RESPONSIBILITIES


  • Lead and conduct in-depth research to investigate off-target effects associated with Mammoth nucleases across various cell types and organisms. Design and execute experiments to characterize off-target events of DSB and non-DSB technologies and identify novel strategies to minimize them effectively
  • Develop, test, and optimize Mammoth’s gene-editing tools to enhance on-target specificity and reduce off-target cleavage
  • Analyze complex genomic datasets, employing bioinformatics tools and computational methods to identify and annotate off-target sites. Interpret data and draw meaningful conclusions to guide further research efforts
  • Design and oversee validation studies to assess the efficacy and safety of newly developed CRISPR reagents and protocols in relevant biological systems. Validate protocols for regulatory submissions
  • Collaboration: Collaborate closely with cross-functional teams, including molecular biologists, cell biologists, bioinformaticians, to integrate off-target findings into ongoing research projects and therapeutic programs
  • Stay updated with the latest advancements in CRISPR and genome-editing technologies. Attend scientific conferences, present research findings, and publish in reputable peer-reviewed journals
  • Ensure compliance with all relevant regulatory guidelines and ethical standards concerning genome editing and gene therapy

REQUIRED QUALIFICATIONS


  • Ph.D. in Molecular Biology, Genetics, Biochemistry, or a related field with a strong focus on genome editing technologies 
  • 4 years minimum of industry experience for Sr. Scientist; 6 years minimum experience (can be combination of post-PhD academic and industry) for Principal Scientist 
  • Proven expertise in gene editing technology, with a specialization in off-target analysis and optimization
  • 4 years experience in experimental design, execution, and data analysis related to genome editing and molecular biology techniques
  • 3 years experience leading and mentoring scientists and collaborating cross functionally

PREFERRED QUALIFICATIONS


  • Experience in utilizing bioinformatics tools and software for the analysis of genomic data and CRISPR off-target prediction
  • Strong track record of scientific publications and contributions to the field of genome editing
  • Excellent problem-solving skills and a passion for innovation in gene-editing technologies
  • Strong written and verbal communication skills, demonstrated by the ability to present complex scientific concepts to technical and non-technical audiences

BENEFITS


  • Company-paid health/vision/dental benefits
  • Unlimited vacation and generous sick time
  • Company-sponsored meals and snacks
  • Wellness, caregiver and ergonomics benefits
  • 401(k) with company matching

Base Salary Range: $ 150,000 - $188,000Actual base salary will be determined by relevant professional experience, applicable skills, and internal equity. COMPANYMammoth Biosciences is a biotechnology company focused on leveraging its proprietary ultracompact CRISPR systems to develop long-term curative therapies, as well as other applications such as decentralized precision diagnostics. Founded by CRISPR pioneer and Nobel laureate Jennifer Doudna and Trevor Martin, Janice Chen, and Lucas Harrington, the company’s ultracompact proteins are designed to enable in vivo gene editing in difficult to reach tissues utilizing both nuclease applications and new editing modalities beyond double stranded breaks, including base editing, gene writing, and epigenetic editing.

The company is building out its pipeline of potential in vivo gene editing therapeutics and capabilities and has partnerships with leading pharmaceutical and biotechnology companies to broaden the reach of its innovative and proprietary technology. Mammoth’s deep science and industry experience, along with a robust and differentiated intellectual property portfolio, have enabled the company to further its mission to transform the lives of patients and deliver on the full promise of CRISPR technologies.It is our policy and intent to provide equal opportunity to all persons without regard to race, color, religion, political affiliation, sex/gender (including gender expression/identity, pregnancy, childbirth and related medical conditions), marital status, registered domestic partner status, sexual orientation, age, ancestry, national origin, veteran status, disability, medical condition, genetic characteristics, and/or any other basis protected by law.  This policy covers all facets of employment including, but not limited to: recruitment, selection, placement, promotions, transfers, demotions, terminations, training, and compensation.Mammoth Biosciences requires that all employees be vaccinated against COVID-19 as a condition of at-will employment, with exceptions for medical or religious reasons in compliance with local, state, and federal law.Apply for this job

This job is no longer open

Life at Mammoth Biosciences

Mammoth Biosciences is harnessing the diversity of nature to power the next-generation of CRISPR products. Through the discovery and development of novel CRISPR systems, the company is enabling the full potential of its platform to read and write the code of life. Mammoth aims to democratize disease detection with an easy and affordable point-of-care test that allows real-time and simultaneous detection of multiple conditions. By leveraging its internal research and development and exclusive licensing to Cas12, Cas13 and Cas14, Mammoth can provide enhanced diagnostics and genome editing for life science research, healthcare, agriculture, biodefense and more. Based in San Francisco, Mammoth Biosciences is co-founded by CRISPR pioneer Jennifer Doudna and principal founders Trevor Martin, Janice Chen, and Lucas Harrington. The firm is backed by top institutional investors including Mayfield, NFX, and 8VC, Decheng and leading individual investors including Brook Byers, Tim Cook, and Jeff Huber.
Thrive Here & What We Value- Unlimited vacation and generous sick time- Company-sponsored meals and snacks- Wellness, caregiver, and ergonomics benefits- 401(k) with company matching- Equal opportunity policy
Your tracker settings

We use cookies and similar methods to recognize visitors and remember their preferences. We also use them to measure ad campaign effectiveness, target ads and analyze site traffic. To learn more about these methods, including how to disable them, view our Cookie Policy or Privacy Policy.

By tapping `Accept`, you consent to the use of these methods by us and third parties. You can always change your tracker preferences by visiting our Cookie Policy.

logo innerThatStartupJob
Discover the best startup and their job positions, all in one place.
Copyright © 2024